Healthy Tomorrows Partnership for Children Program (HTPC)
This Final Rule sets forth the Secretary's proposal to require HTPC grant recipients to contribute non-Federal matching funds in years 2 through 5 of the project period equal to two times the amount of the Federal Grant Award or such lesser amount determined by the Secretary for good cause shown.
Establishment of Advisory Council on Blood Stem Cell Transplantation and Solicitation of Nominations for Membership
Pursuant to Public Law 109-129, 42 U.S.C. 274k (section 379 of the Public Health Service Act, as amended) and the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), the Administrator, HRSA, announces the establishment of the Advisory Council on Blood Stem Cell Transplantation by the Secretary, HHS. The Council will advise the Secretary on proposed C.W. Bill Young Cell Transplantation Program policies and other such matters as the Secretary determines. Duration of this Council is for two years unless renewed by the Secretary, HHS. This notice also requests nominations for membership on the Council.
Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Definition of “Patient”
Section 602 of Public Law 102-585, the ``Veterans Health Care Act of 1992,'' enacted Section 340B of the Public Health Service (PHS) Act ``Limitation on Prices of Drugs Purchased by Covered Entities.'' Section 340B provides that in order to obtain Medicaid reimbursement for its covered outpatient drugs, a manufacturer must sign a pharmaceutical pricing agreement with the Secretary of Health and Human Services in which the manufacturer agrees to charge a price to covered entities for outpatient drugs that will not exceed an amount determined under a statutory formula. Section 340B is administered as the ``340B Drug Pricing Program'' and is commonly referred to as ``the 340B Program.'' Section 340B states that it is illegal for covered entities to sell medications purchased under the 340B Program to persons who are not considered ``patients'' of the covered entity. The purpose of this notice is to inform interested parties of proposed clarifications to the definition of ``patient'' for whom the covered entity can purchase discounted pharmaceuticals under the 340B Program. This clarification is necessary to protect the integrity of the 340B Program and to assist covered entities and other participants in their compliance efforts.
Notice Regarding 340B Drug Pricing Program-Contract Pharmacy Services
Section 340B of the Public Health Service Act implements a drug pricing program in which manufacturers who sell covered outpatient drugs to covered entities must agree to charge a price that will not exceed an amount determined under a statutory formula. The purpose of this notice is to inform interested parties of proposed guidelines regarding contract pharmacy services that will allow covered entities to utilize contract pharmacy services arrangements previously limited to the Alternative Methods Demonstration Project program.
Advisory Committee on Organ Transplantation
The Advisory Committee on Organ Transplantation (ACOT) will be conducting a conference call to discuss the revision of the Uniform Anatomical Gift Act (UAGA).
National Vaccine Injury Compensation Program; List of Petitions Received
The Health Resources and Services Administration (HRSA) is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (``the Program''), as required by Section 2112(b)(2) of the Public Health Service (PHS) Act, as amended. While the Secretary of Health and Human Services is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.